Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder.
OBJECTIVE
We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.


METHODS
A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).


RESULTS
There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.


CONCLUSIONS
Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
Yun
Dong-Hwan
DH
Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Pae
Chi-Un
CU
Drago
Antonio
A
Mandelli
Laura
L
De Ronchi
Diana
D
Patkar
Ashwin A
AA
Paik
In Ho
IH
Serretti
Alessandro
A
Kim
Jung-Jin
JJ